NCT05998941

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ Study

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
DRUG	TQB2868 injection	TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
DRUG	Paclitaxel injection	Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
DRUG	Cisplatin injection	Cisplatin injection can inhibit the DNA replication process of cancer cells
DRUG	Carboplatin injection	Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
DRUG	Bevacizumab injection	Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).

Timeline

• Start date: 2023-08-01
• Primary completion: 2025-02-01
• Completion: 2025-06-01
• First posted: 2023-08-21
• Last updated: 2023-11-22

Locations

2 sites across 1 country: China